(Q36194078)

12 August 2017

1 reference

title

Carriers for the delivery of a vaccine against respiratory syncytial virus (English)

1 reference

12 August 2017

1

Martin Cranage

1 reference

12 August 2017

2

Geraldine Taylor

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

Expert Opinion on Biological Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

7

1 reference

12 August 2017

page(s)

939-952

1 reference

Respiratory syncytial virus. Brief review

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Mortality associated with influenza and respiratory syncytial virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Respiratory syncytial virus in healthy adults: the cost of a cold

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Respiratory syncytial virus and influenza A infections in the hospitalized elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Respiratory syncytial virus immunobiology and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

A role for immune complexes in enhanced respiratory syncytial virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Mechanism of lung injury in cotton rats immunized with formalin-inactivated respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Vaccine-Induced Immunopathology during Bovine Respiratory Syncytial Virus Infection: Exploring the Parameters of Pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Increased replication of respiratory syncytial virus (RSV) in pulmonary infiltrates is associated with enhanced histopathological disease in bonnet monkeys (Macaca radiata) pre-immunized with a formalin-inactivated RSV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

A cautionary note on experimental artefacts induced by fetal calf serum in a viral model of pulmonary eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Pandoraea bacteremia in a cystic fibrosis patient with associated systemic illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Immunity to and frequency of reinfection with respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Respiratory syncytial virus: reverse genetics and vaccine strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Role of alpha/beta interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Appearance of a soluble form of the G protein of respiratory syncytial virus in fluids of infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Distinct patterns of T- and B-cell immunity to respiratory syncytial virus induced by individual viral proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Nonreplicating vaccinia vector efficiently expresses recombinant genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type 14 vector is immunogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Efficacy of adenovirus-vectored respiratory syncytial virus vaccines in a new ferret model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Gene-gun DNA vaccination aggravates respiratory syncytial virus-induced pneumonitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

T helper 2 immunity to hepatitis B surface antigen primed by gene-gun-mediated DNA vaccination can be shifted towards T helper 1 immunity by codelivery of CpG motif-containing oligodeoxynucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

An assessment of different DNA delivery systems for protection against respiratory syncytial virus infection in the murine model: gene-gun delivery induces IgG in the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

DNA vaccination against respiratory syncytial virus in young calves

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Technical issues in construction of nucleic acid vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

DNA-encoded fetal liver tyrosine kinase 3 ligand and granulocyte macrophage-colony-stimulating factor increase dendritic cell recruitment to the inoculation site and enhance antigen-specific CD4+ T cell responses induced by DNA vaccination of outbre

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Jump-starting the immune system: prime-boosting comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Vaccination of cotton rats with a chimeric FG glycoprotein of human respiratory syncytial virus induces minimal pulmonary pathology on challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Human respiratory syncytial virus vaccine antigen produced in plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Oral immunization of mice with transgenic tomato fruit expressing respiratory syncytial virus-F protein induces a systemic immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Safety and efficacy of immune-stimulating complex-based antigen delivery systems for neonatal immunisation against respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Enhanced immune protection by a liposome-encapsulated recombinant respiratory syncytial virus (RSV) vaccine using immunogenic lipids from Deinococcus radiodurans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Bovine respiratory syncytial virus nonstructural proteins NS1 and NS2 cooperatively antagonize alpha/beta interferon-induced antiviral response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Immunoregulatory role of secreted glycoprotein G from respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Respiratory syncytial virus induces prostaglandin E2, IL-10 and IL-11 generation in antigen presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Respiratory syncytial virus decreases the capacity of myeloid dendritic cells to induce interferon-gamma in naïve T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Recombinant vaccinia viruses expressing the F, G or N, but not the M2, protein of bovine respiratory syncytial virus (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

Differential Expression of Proinflammatory Cytokine Genes In Vivo in Response to Pathogenic and Nonpathogenic Pneumovirus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.7.939

21 January 2018

Identifiers

DOI

10.1517/14712598.5.7.939

1 reference

12 August 2017

1 reference